Table 1.

Comparison of cytokine and soluble receptor levels in animals treated with anti-VEGF therapy

ControlBevacizumabr842C3
Tumor*SerumTumorSerumTumorSerumTumorSerum
Ms VEGF43.4 (3.3), n = 622.88 (7.0), n = 845.1 (1.8), n = 220.24 (5.4), n = 642.1 (3.3), n = 3ND, n = 347.1 (3.9), n = 544.81 (13.6), n = 8
Hu PlGF49.9 (2.7), n = 432.78 (6.0), n = 32.4 (0.5), n = 230.91 (8.7), n = 342.6 (1.9), n = 433.92 (6.2), n = 344.9 (11.0), n = 326.53 (3.6), n = 3
Ms PlGF49.1 (3.8), n = 352.72 (15.8), n = 343.7 (12.9), n = 317 (4.7), n = 475.2 (4.6), n = 332.02 (12.1), n = 343.2 (8.1), n = 434.02 (9.5), n = 3
Hu sVEGFR11.9 (1.2), n = 4ND; n = 4ND, n = 2ND, n = 30.5 (0.8), n = 4ND, n = 31.5 (1.0), n = 5ND, n = 5
Ms sVEGFR1734.6 (49.9), n = 3480.9 (68.2), n = 3394.8 (5.5),n = 2906.4 (15.9), n= 2479 (36.5), n = 4429.2 (52.3), n = 3344.2 (28.9), n = 3568.7 (76.1), n = 3
Ms sVEGFR286.98 (2.6), n = 682.12 (2.6), n = 388.16 (0.5), n = 391.68 (3.0), n = 6

NOTE: Mean (SE) is displayed. n is the number of tumors from the indicated group assayed in triplicate.

Abbreviation: ND, not determined; MS, mouse; Hu, human.

  • *Picogram per 100 μg of tumor lysate.

  • Picogram per milliliter of serum.

  • Values in bold are statistically significant compared with control; all P < 0.01 or P < 0.001 by one-way ANOVA and Bonferroni's multiple comparison test.